Oncology Breakfast Briefing 2026

💡 From organ-based oncology to biomarker-driven oncology: who will make tomorrow’s decisions?

The rise of genomic platforms, molecular profiling, and biomarker-guided therapies is gradually reshaping the organization of oncology. Tumor location alone is no longer always sufficient to guide treatment strategies. Instead, the identification, testing, and interpretation of biomarkers are playing an increasingly central role in therapeutic decision-making.

🧭 But where do we really stand today in this transition?

At this briefing, APLUSA will bring together healthcare experts and pharmaceutical industry stakeholders to explore these evolving dynamics, understand how they are reshaping roles across the care pathway, and anticipate their implications for patient management and industry strategies.

• Where do we stand today in the organization of biomarker testing?
• How are the respective roles of Multidisciplinary Tumor Boards (MDTs) and Molecular Tumor Boards evolving?
• What role is AI already playing in interpretation and decision-making, and what role could it play in the future?
• How are these developments redefining the roles of the various stakeholders involved in therapeutic decision-making?

🥟 A complimentary buffet will be served after the briefing to continue the discussions.